DS
KRTX

David Shaw’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

David Shaw’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,131
Closed -$6.06M – 4867
2023
Q4 		$6.06M Sell
19,131
-20,353
-52% -$3.96M 0.01% 1754
2023
Q3 		$6.68M Sell
39,484
-79,842
-67% -$15M 0.01% 1576
2023
Q2 		$25.9M Buy
119,326
+11,907
+11% +$2.55M 0.03% 741
2023
Q1 		$19.5M Sell
107,419
-169,761
-61% -$32.5M 0.02% 912
2022
Q4 		$54.5M Sell
277,180
-40,940
-13% -$8.78M 0.06% 401
2022
Q3 		$71.6M Buy
318,120
+312,660
+5,726% +$63.3M 0.09% 257
2022
Q2 		$691K Buy
+5,460
New +$628K ﹤0.01% 3868
2021
Q4 		– Sell
-16,285
Closed -$1.99M – 5803
2021
Q3 		$1.99M Sell
16,285
-964
-6% -$111K ﹤0.01% 3040
2021
Q2 		$1.97M Buy
+17,249
New +$2.02M ﹤0.01% 2957
2020
Q3 		– Sell
-7,211
Closed -$804K – 4253
2020
Q2 		$804K Buy
+7,211
New +$627K ﹤0.01% 3073
2020
Q1 		– Sell
-27,118
Closed -$2.04M – 4351
2019
Q4 		$2.04M Buy
+27,118
New +$1.19M ﹤0.01% 2451

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

David Shaw's KRTX Position: Q1 2024 in Review

David Shaw sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 19,131 shares — an estimated $6.06M sold.

David Shaw first reported a position in KRTX in Q4 2019 and held it in 11 quarters. The position peaked at $71.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • David Shaw reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • David Shaw sold 19,131 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.06M.
  • David Shaw first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • David Shaw's Karuna Therapeutics, Inc. Common Stock position peaked at $71.6M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.